Biocon plots new deals after sale of enzymes business

The Business Standard is providing a little more illumination on Biocon's acquisition plans. Flush from the $115 million sale of its enzymes business, the Indian company says it will look to either make investments in other biopharma companies or buy them out entirely as the company stays focused on pharma. Biocon's business centers on APIs, biologicals and proprietary molecules.

"Over the past decade, we have recognized the high growth trajectory of biopharma business verticals and progressively invested in building proprietary know-how and global scale. We believe this is the right time to divest our enzymes business and focus on unleashing the full potential of our biopharma businesses," said Biocon Managing Director Kiran Mazumdar-Shaw.

- check out Biocon's release
- here's the Business Standard report

Suggested Articles

Bristol Myers Squibb may have bounced Jounce from its roster of inherited partners, but it’s hanging onto Anokion, a Swiss autoimmune-focused biotech.

The priority review action date sets Bristol Myers up to win approval for the bluebird-partnered anti-BCMA CAR-T therapy in late March.

The unidentified biotechs are drawn from the portfolio of a €150 million life science-focused fund that Index Ventures set up.